Skip to main content
. 2020 Mar 11;55(6):e4506. doi: 10.1002/jms.4506

Figure 5.

Figure 5

Chromatographic profile of a plasma from one HIV‐infected individual receiving bictegravir 50 mg once daily (A) and from another patient receiving doravirine 100 mg once daily (B) [Colour figure can be viewed at wileyonlinelibrary.com]